A global leader in digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.
Global
Joined July 2015
- Tweets277
- Following205
- Followers278
- Likes163
CEO Dawn Bitz and Chief Commercial Officer John Perry recently provided an investor update on #Adherium's pathway to value-based care in the US.
Here's the replay: bit.ly/ADR_VBC_briefing
$ADR #digitalhealth #respiratory #healthcare #remotepatientmonitoring #valuedbasedcare
@Adherium has today released the revised time for its investor webinar - 10:30am AEST 25 June 2026. CEO Dawn Bitz and CCO John Perry will outline how the Company is positioning itself to secure Value Based Care (VBC) contracts. Register now: bit.ly/ADRJuneWebinar2026 $ADR
Equity analysts MST Access have released a report highlighting Adherium’s major value.
Read the full report: bit.ly/4dK20st
$ADR #Adherium #digitalhealth #respiratoryhealth #asthma #innovation #healthcare
Adherium has presented the first dataset from its RPM program, showing only 8.3% of asthma patients demonstrated optimal inhaler technique using objective Hailie® Smartinhaler® data.
Read the ASX release: bit.ly/4u7d7jX
$ADR #RPM #DigitalHealth #Asthma
Adherium has appointed John Perry as Chief Commercial Officer to lead integrated global commercial operations and support expansion into value-based respiratory care.
Read the ASX release: bit.ly/4o2vyVL
$ADR #DigitalHealth #RPM #ValueBasedCare
Two independent studies were presented at the ATS 2026 International Conference, featuring data using Adherium’s Hailie® Smartinhaler® technology.
Together, they reinforce the role of objective respiratory monitoring in improving patient outcomes.
🔗 bit.ly/3PYyUMJ
Today is World Asthma Day. The future of asthma care lies in making invisible visible - using continuous data to better understand and support how patients manage their condition. @Adherium is leading this shift. #WorldAsthmaDay
@Adherium has today released its quarterly report for the period ending 31 March 2026, highlighting continued acceleration in recurring RPM revenue and commercial execution.
Read the ASX release: bit.ly/4mY5zy9
Adherium has announced new real-world results from the iCARE study, showing a 67% reduction in hospitalisations and 46% reduction in total cost of care for patients using the Hailie® Smartinhaler® platform.
Read the ASX release: bit.ly/46QwqFv
@Adherium has released a sales update highlighting continued commercial momentum behind its Hailie® Smartinhaler® platform and Remote Patient Monitoring (RPM) model.
Read the ASX release: bit.ly/4cGfNA1
CEO Dawn Bitz recently provided an investor update on Adherium’s accelerating commercial progress, interim data from the landmark iCARE Study, and the recently completed capital raise.
Here’s the replay: youtu.be/DRUzspwesKo
Adherium (ASX:ADR) has announced that it has received firm commitments for a total of $6.70 million under the Placement and institutional component of the Accelerated Pro-Rata Non-Renounceable Entitlement Offer (ANREO).
Read the ASX announcement: bit.ly/4rmeNFz
Adherium has today announced a capital raising of up to approximately A$7.52 million through a Placement and a 1-for-1.5 pro-rata accelerated non-renounceable Entitlement Offer.
Read the ASX announcement: bit.ly/3OaZXDs
In this investor update, CEO Dawn Bitz outlines Adherium’s progress in respiratory digital health, highlighting momentum in its remote patient monitoring program and continued growth in recurring revenue.
Watch the presentation: youtu.be/E-yiPMVHMak